Clinical Study
Amoxicillin/Clavulanic Acid for the Treatment of Odontogenic Infections: A Randomised Study Comparing Efficacy and Tolerability versus Clindamycin
Table 3
Secondary endpoint: change in VAS scores for pain and swelling from baseline.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note: change from baseline in VAS for assessment of pain and swelling was analysed using a mixed model for repeated measures (MMRM) with restricted maximum likelihood and an unstructured covariance matrix. The baseline VAS score was used as a covariate. Treatment groups and nominal days (visits) were considered as fixed effects and interaction effect was considered between treatment and visit (days). Data for “Day 7” is summarised for subjects who continued the study up to Day 7. OC method was used for missing values where the missing value was kept as missing except for early withdrawal. “” indicates Day 2, or Day 5, or Day 7 as applicable. LCL: lower confidence limit, UCL: upper confidence limit. means the interaction effect between treatment and visits (days). |